Here's what I know... On December 2nd, Todos Me
Post# of 30027
(Total Views: 310)
Posted On: 01/22/2022 7:06:10 PM
Here's what I know...
On December 2nd, Todos Medical Announces all 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
In that PR on Dec. 2nd, the Company said they expect the data analysis to be completed in December 2021
They didn't say it will. Too many things outside their control. They said they expect. Unfortunately covid gets in the way.
For those that may ask, why does any company give any dates since nothing is ever certain? Well, if they said, we are going to finish sometime in the future, it wouldn't go well and/or twitter trolls fingers would start bleeding. If I was Gerald, I would ignore them and not waste a second. You have a combination of new twitter accounts because the others got canned, first stock buyers and people way, way, way over their skis.
They also didn't say they would announce results, they said they expect the data analysis to be completed. No different than me telling my wife I 'expect' to do well in a stock and she hears 'will'.
On Jan 10th. Gerald said "the biomarker data is now being run and put into the electronic data capture system before the data can be locked for statistical analysis. Should be done in the next few days then QC before formal data lock so the analysis will be very short"
I was thinking, thank goodness they are using the electronic system instead of punch cards. In biotech, they still use old terminology.
Does someone look at the data before the data lock? idk, what are the rules?
Does someone look at the biomarker data after it run? idk, what are the rules?
I would think the most important part is to lock in your end points before looking at the data. When were those endpoints locked? Does that happen before the data lock? I would think so, but what do I know.
There are not a lot of end points in this trial nor many biomarkers. Analysis, as Gerald said, should be quick. Me thinks an hour.
Coincidence Gerald was on Fox on Jan. 11th.
Next day Jan 12th, they announced they will present the results on January 27th
Why would you pick a date in about two weeks in this uncertain world unless you already have a pretty, pretty, pretty good feeling?
In that PR they said "The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial."
Week ending 17th would be Sunday Jan. 23, so Gerald updates shareholder Monday instead.
Here's what we know...
3cl protease inhibitors work. If you have doubts, give Pfizer a call.
Tollovir is a 3cl protease inhibitor
It worked great in the observational trial
Now did the 11 people get better, faster, stronger and not die because they willed it as they thought they were getting a miracle drug?
I'd find that hard to think that would be possible, but anything is possible. My money is on, Tollovir works. So far, those that I know with a bottle of Tollovid, haven't contracted Covid or if they did, it never reared it's ugly head.
The big question for me is, does it prevent the cytokine storm. Well, for those 11 it appeared it did. Feel bad for the people that didn't get Tollovir including the 5 that died.
Did Todos just get plain lucky, I doubt it. You would think there were others on the way to the hospital or in the hospital where someone tried Tollovid or Tollovir. Not like Tollovid needs a prescription which makes it very compelling.
So what happens if the anti-cytokine doesn't work? Then Tollovid makes a dam good product for outpatients, mild, moderate.
I posted on the Todos board, Zicam sold for 1/2 billion in 2020 and that is easily replicated too.
What's funny about Tollovid. I don't even have to convince people to buy it, especially if they were exposed to Covid, have a sniffle, scratchy throat, etc. I really thought I would, but it's usually a 1 minute conversation.
Now back to my NFL arm chair quarterbacking
On December 2nd, Todos Medical Announces all 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
In that PR on Dec. 2nd, the Company said they expect the data analysis to be completed in December 2021
They didn't say it will. Too many things outside their control. They said they expect. Unfortunately covid gets in the way.
For those that may ask, why does any company give any dates since nothing is ever certain? Well, if they said, we are going to finish sometime in the future, it wouldn't go well and/or twitter trolls fingers would start bleeding. If I was Gerald, I would ignore them and not waste a second. You have a combination of new twitter accounts because the others got canned, first stock buyers and people way, way, way over their skis.
They also didn't say they would announce results, they said they expect the data analysis to be completed. No different than me telling my wife I 'expect' to do well in a stock and she hears 'will'.
On Jan 10th. Gerald said "the biomarker data is now being run and put into the electronic data capture system before the data can be locked for statistical analysis. Should be done in the next few days then QC before formal data lock so the analysis will be very short"
I was thinking, thank goodness they are using the electronic system instead of punch cards. In biotech, they still use old terminology.
Does someone look at the data before the data lock? idk, what are the rules?
Does someone look at the biomarker data after it run? idk, what are the rules?
I would think the most important part is to lock in your end points before looking at the data. When were those endpoints locked? Does that happen before the data lock? I would think so, but what do I know.
There are not a lot of end points in this trial nor many biomarkers. Analysis, as Gerald said, should be quick. Me thinks an hour.
Coincidence Gerald was on Fox on Jan. 11th.
Next day Jan 12th, they announced they will present the results on January 27th
Why would you pick a date in about two weeks in this uncertain world unless you already have a pretty, pretty, pretty good feeling?
In that PR they said "The Company will provide further details regarding the conference call during the week ending January 17, 2022 when it announces the data lock for the trial."
Week ending 17th would be Sunday Jan. 23, so Gerald updates shareholder Monday instead.
Here's what we know...
3cl protease inhibitors work. If you have doubts, give Pfizer a call.
Tollovir is a 3cl protease inhibitor
It worked great in the observational trial
Now did the 11 people get better, faster, stronger and not die because they willed it as they thought they were getting a miracle drug?
I'd find that hard to think that would be possible, but anything is possible. My money is on, Tollovir works. So far, those that I know with a bottle of Tollovid, haven't contracted Covid or if they did, it never reared it's ugly head.
The big question for me is, does it prevent the cytokine storm. Well, for those 11 it appeared it did. Feel bad for the people that didn't get Tollovir including the 5 that died.
Did Todos just get plain lucky, I doubt it. You would think there were others on the way to the hospital or in the hospital where someone tried Tollovid or Tollovir. Not like Tollovid needs a prescription which makes it very compelling.
So what happens if the anti-cytokine doesn't work? Then Tollovid makes a dam good product for outpatients, mild, moderate.
I posted on the Todos board, Zicam sold for 1/2 billion in 2020 and that is easily replicated too.
What's funny about Tollovid. I don't even have to convince people to buy it, especially if they were exposed to Covid, have a sniffle, scratchy throat, etc. I really thought I would, but it's usually a 1 minute conversation.
Now back to my NFL arm chair quarterbacking
(2)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼